PharmaTher Secures FDA Meeting for Ketamine Drug

PharmaTher Holdings Ltd (TSE:PHRM) has released an update.

PharmaTher Holdings Ltd. has secured a meeting with the FDA to address a complete response letter regarding its ketamine drug application, aiming to resolve minor deficiencies. The company is focused on meeting FDA guidelines to help alleviate the ongoing ketamine shortage in the U.S., where ketamine has been in short supply since 2018.

For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.